A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

Prior treatment

• Any change in established pulmonary treatment (including antibiotics) within 28 days prior to Screening Visit. However, inhaled beta-agonists can be included within 2 weeks prior to Screening Visit.
• Clinically significant episode of hemoptysis (\>50 mL or ¼ cup or 10 teaspoons per day) within 12 weeks prior to dosing with study drug on Day 1
• Currently receiving treatment for active lung infection with Burkholderia cenocepacia or Burkholderia dolosa
• Current active fungal infection (not just a positive culture), acute blood, lung, or bladder infection, clinically significant hepatic or renal dysfunction, and/or viral infection (including human immunodeficiency virus or hepatitis virus B or C) requiring the initiation of new therapy within 30 days prior to Screening
• Subjects who received any investigational products within 30 days (or 5 therapeutic half-lives, whichever is longer) prior to Screening
• Subjects who have previously received any gene therapy agent

Other illness

• Lung infection with Mycobacterium abscessus associated with a more rapid decline in pulmonary status
• History of solid organ or hematological transplantation
• History of clinically significant cirrhosis with or without portal hypertension
• History of pulmonary hypertension
• History of cardiotoxicity, a history of known coronary artery disease, and/or existing cardiomyopathy
• History of allergic bronchopulmonary aspergillosis (ABPA)

Lab values

• Uncontrolled diabetes mellitus, as evidenced by hemoglobin A1c \>9% at Screening
• Clinically significant laboratory abnormalities at Screening
• Subjects with any medical condition or abnormal laboratory result that, in the opinion of the Investigator, will interfere with the safe completion of the study

Other

• Subjects with known sensitivity to SP-101, doxorubicin or its excipients

• Males or females, age 18 to 65 years at Screening Visit, inclusive
• Diagnosis of CF
• ppFEV1 value between 50-100% (inclusive)
• Resting oxygen saturation ≥94% on room air by pulse oximetry 5 . Clinically stable CF disease as assessed by the Investigator and not requiring any new class of interventional treatment within the last 3 months prior to Screening